

Leveraging functional genomics to reveal novel targets for cancer treatment

Horizon Europe

Generato il: 8 ottobre 2026

● IN ATTESA

Codice

HORIZON-MISS-2027-02-CANCER-01

Ambito

Internazionale

Località

Europa

Curatore

Marlene Faria

Dettagli Finanziari

Tipo di supporto

Fondo perduto

Tasso Massimo di Finanziamento

100%

Budget

3.2B€

Valore di Progetto Ammissibile

7M€ - 8M€

Date e Scadenze

Data di Pubblicazione

Non definita

Data di Apertura

10 febbraio 2027

Fase unica

16 settembre 2027 alle ore 17:00 GMT+2

Descrizione

Objectives

This topic aims to advance the understanding of cancer initiation, progression and treatment resistance through the application of functional genomics and multi-omics approaches, contributing directly to the objectives of the EU Cancer Mission. Particular attention is given to paediatric and adolescent cancers, rare cancers, refractory cancers, cancers with limited treatment options, and tumour types with low survival rates. Projects are expected to identify and validate novel therapeutic targets, improve understanding of tumour heterogeneity and resistance mechanisms, and support the development of next-generation genomically informed cancer treatments. Applicants are encouraged to leverage advanced technologies such as single-cell analysis, spatial transcriptomics, liquid biopsies, epigenetic profiling, AI, computational modelling and precision oncology approaches.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of around €32 million, with the European Commission expecting to fund approximately four projects. The expected EU contribution is between €7 million and €8 million per project, although proposals requesting different amounts may also be considered where appropriately justified. As a Research and Innovation Action, projects are eligible for 100% funding of eligible costs in accordance with Horizon Europe rules.

Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Idoneità

Settori Idonei

Salute e Life Sciences

Modalità di Candidatura

Aggregata / Partenariato

Tipologie Aziendali

- Microimpresa
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande impresa
- Enti di ricerca
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Research and Innovation Actions
- Clinical Trials
- Digital Health Solutions
- Cross-Border Integration

Dettagli Programma UE

ID Bando

HORIZON-MISS-2027-02-CANCER-01

Cluster

Mission

Destinazione

Cancer

Modalità di Presentazione

Single-stage

Contributo UE

Around €7,000,000.00 to €8,000,000.00 per project

Progetti Previsti

4

Regola del Tasso di Finanziamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Link Ufficiali

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-01?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-01&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/leveraging-functional-genomics-to-reveal-novel-targets-for-cancer-treatment>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabled>